Pyronaridine–Artesunate versus Mefloquine plus Artesunate for Malaria

Journal article

BACKGROUND: Pyronaridine-artesunate is an artemisinin-based combination therapy under evaluation for the treatment of Plasmodium falciparum and P. vivax malaria. METHODS: We conducted a phase 3, open-label, multicenter, noninferiority trial that included 1271 patients between 3 and 60 years of age from Asia (81.3%) or Africa (18.7%) with microscopically confirmed, uncomplicated P. falciparum malaria. Patients underwent randomization for treatment with a fixed-dose combination of 180 mg of pyr...

Expand abstract

Authors: Rueangweerayut, R; Phyo, A; Uthaisin, C; Poravuth, Y; Binh, T

• Publication status: Published
• Peer review status: Peer reviewed
• Publisher: Massachusetts Medical Society Publisher's website
• Journal: New England Journal of Medicine Journal website
• Volume: 366
• Issue: 14
• Pages: 1298-1309
• Publication date: 2012-04-05
• DOI: 10.1056/NEJMoa1007125
• EISSN: 1533-4406
• ISSN: 0028-4793
• Pmid: 22475593
• Language: English
• Keywords: Drug Resistance; Mefloquine; Naphthyridines; Adult; Artemisinins; Male; Pyronaridine–Artesunate Study Team; Young Adult; Antimalarials; Malaria, Falciparum; Child, Preschool; SBTMR; Humans; Female; Adolescent; Journal Article; Middle Aged; Randomized Controlled Trial; Africa; Asia; Clinical Trial, Phase III; Intention to Treat Analysis; Comparative Study; Research Support, Non-U.S. Gov't; Kaplan-Meier Estimate; Child; Drug Combinations; Proportional Hazards Models